Kalra Sanjay, Unnikrishnan Ambika G, Agrawal Navneet, Singh Anupam K
Bharti Hospital, Karnal, Haryana, India.
Recent Pat Endocr Metab Immune Drug Discov. 2011 Sep;5(3):197-202. doi: 10.2174/187221411797265926.
The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. These agents may be used either as monotherapy for the treatment of type-2 diabetes or in combination with other anti-diabetic drugs. The present review highlights the use of linagliptin and other new (DPP-4) inhibitors in the management of type-2 diabetes. The review also highlights advantages, comparative pharmacokinetic, safety profile and other potential uses including potential newer indications of DPP-4 inhibitors and relevant patents. The other potential uses that are not restricted to diabetes include obesity, cardiovascular disease, neurological disease, hepatobiliary disease, wound healing, and other inflammatory illnesses.
二肽基肽酶-4（DPP-4）抑制剂利格列汀、西格列汀、沙格列汀、维格列汀和阿格列汀正在研发中，并已获批用于治疗2型糖尿病。这些药物既可以作为单药治疗2型糖尿病，也可以与其他抗糖尿病药物联合使用。本综述重点介绍了利格列汀和其他新型（DPP-4）抑制剂在2型糖尿病管理中的应用。该综述还强调了其优势、比较药代动力学、安全性概况以及其他潜在用途，包括DPP-4抑制剂潜在的新适应症和相关专利。其他不限于糖尿病的潜在用途包括肥胖症、心血管疾病、神经系统疾病、肝胆疾病、伤口愈合以及其他炎症性疾病。
